Methods for predicting drug response
AssigneeCeltrix Pharmaceuticals, Inc.
InventorDesmond Mascarenhas
Life of this patent
Estimating the term…
Abstract
Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or biochemical parameters) for a test group before and after treatment with the drug or regimen. These values are used formulate a specific predictive method for the particular drug or treatment regimen. The predictive measurement is then used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen.
Claims6
A method for predicting the effect of the administration of insulin-like growth factor I (IGF-I) on serum levels of procollagen peptide (C1CP) and IGFBP-3 in a subject, comprising:
- measuring the subject's serum level of thyroid stimulating hormone ("TSH!");
- measuring the subject's serum level of total tetraiodothyronine ("tT4!");
- measuring the subject's serum level of IGF-I ("IGF-I!");
- and calculating said subject's responsiveness by the formula ##EQU2## wherein P is the subject's responsiveness, TSH! is the basal concentration of TSH in micro international units per milliliter of serum (.mu.IU/mL), tT4! is the basal concentration of total T4 in nanograms per milliliter of serum (ng/mL), and IGF-I! is the basal concentration of IGF-I in ng/mL.
A method for predicting the effect of the administration of insulin-like growth factor I (IGF-I) on serum levels of procollagen peptide (C1CP) in a subject, comprising:
- measuring the subject's serum level of thyroid stimulating hormone ("TSH!");
- measuring the subject's serum level of total tetraiodothyronine ("tT4!");
- measuring the subject's serum level of IGF-I ("IGF-I!");
- and calculating said subject's responsiveness by the formula ##EQU3## wherein P is the subject's responsiveness, TSH! is the basal concentration of TSH in micro international units per milliliter of serum (.mu.IU/mL), tT4! is the basal concentration of total T4 in nanograms per milliliter of serum (ng/mL), and IGF-I! is the basal concentration of IGF-I in ng/mL.
A method for predicting the effect of the administration of insulin-like growth factor I (IGF-I) on serum levels of IGFBP-3 in a subject, comprising:
- measuring the subject's serum level of thyroid stimulating hormone ("TSH!");
- measuring the subject's serum level of total tetraiodothyronine ("tT4!");
- measuring the subject's serum level of IGF-I ("GF-I!");
- and calculating said subject's responsiveness by the formula ##EQU4## wherein P is the subject's responsiveness, TSH! is the basal concentration of TSH in micro international units per milliliter of serum (.mu.IU/mL), tT4! is the basal concentration of total T4 in nanograms per milliliter of serum (ng/mL), and IGF-I! is the basal concentration of IGF-I in ng/mL.
A diagnostic kit for predicting a subject's responsiveness to an insulin-like growth factor I (IGF-I) drug or treatment regiment, comprising:
- at least one set of reagents for measuring biochemical parameters, resulting in at least one biochemical value;
- and
- a means for utilizing one or more biochemical values to predict the subject's responsiveness to said IGF-I drug or treatment regimen,
- wherein said biochemical parameters are selected from the group consisting of serum thyroid stimulating hormone ("TSH!"), total serum tetraiodothyronine ("tT4!"), and serum IGF-I ("IGF-I!"), and said predictive relationship is ##EQU5## and P is said subject's responsiveness to said IGF-I drug or treatment regimen.
Dependencies are inferred from the claim text.